Sugi Predict

Sugi Predict / Compounds / SCHEMBL3201396

SCHEMBL3201396

SCHEMBL3201396

NS(=O)(=O)c1ccc(N2C(=O)[C@@H]3[C@@H]4CC[C@@H](C4)[C@@H]3C2=O)cc1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.65
▸ SMN1; SMN2 Q16637 2/20 0.65
▸ CA1 P00915 9/20 0.59
▸ CA2 P00918 9/20 0.59
▸ CA9 Q16790 9/20 0.59
▸ CA12 O43570 8/20 0.59
▸ ALDH1A1 P00352 2/20 0.59
▸ TDP1 Q9NUW8 1/20 0.59
▸ LMNA P02545 1/20 0.59
▸ NPC1 O15118 1/20 0.58
▸ RAB9A P51151 1/20 0.58
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ CA4 P22748 1/20 0.49
▸ CA7 P43166 2/20 0.49
▸ SCN2A Q99250 1/20 0.47
▸ MT-CO2 P00403 3/20 0.47
▸ ALOX5 P09917 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3201402 1.00 POLB (0.65) POLBSMN1; SMN2CA1CA2CA9
SCHEMBL5922816 0.84 SMN1; SMN2 (0.62) POLBSMN1; SMN2CA1CA2CA9
SCHEMBL5922809 0.84 SMN1; SMN2 (0.62) POLBSMN1; SMN2CA1CA2CA9
SCHEMBL3188954 0.81 POLB (0.65) POLBSMN1; SMN2CA1CA2CA9
SCHEMBL1957622 0.80 CA2 (0.76) POLBSMN1; SMN2CA1CA2CA9
SCHEMBL20118874 0.78 CA2 (0.71) POLBSMN1; SMN2CA1CA2CA9
SCHEMBL13483841 0.76 POLB (0.58) POLBSMN1; SMN2CA1CA2CA9
SCHEMBL3203807 0.76 POLB (0.58) POLBSMN1; SMN2CA1CA2CA9
SCHEMBL10038045 0.76 MEN1 (0.85) POLBSMN1; SMN2ALDH1A1TDP1LMNA
SCHEMBL18830966 0.76 MEN1 (0.85) POLBSMN1; SMN2ALDH1A1TDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060111424-A1 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function SALVATI MARK E 2006-05-25 — — US claimed
US-20040087548-A1 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function BRISTOL-MYERS SQUIBB COMPANY 2004-05-06 — — US claimed
US-7655688-B2 Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-02 — — US disclosed
US-20060111424-A1 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function SALVATI MARK E 2006-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087548-A1 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function NCOA1, ESRRA, NR5A1 POLB 3096/4885SMN1; SMN2 3782/4885CA1 3308/4885
US-20060111424-A1 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function NCOA1, ESRRA, NR5A1 POLB 3096/4885SMN1; SMN2 3782/4885CA1 3308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.